Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study
Bibliographic record
Abstract
BACKGROUND: There are no approved therapies for patients with milder hidradenitis suppurativa (HS), and available treatments are often inadequate. OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib (Janus kinase 1 and Janus kinase 2 inhibitor) cream in adults with mild to moderate HS. METHODS: This phase 2 study enrolled adults with Hurley stage I/II HS and abscess and inflammatory nodule (AN) count 3-10 with no draining tunnels. Patients were randomized 1:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 16 weeks, after which all patients applied ruxolitinib cream as needed through week 32. The primary endpoint was change from baseline in AN count at week 16. RESULTS: Sixty-nine patients were randomized. At week 16, change from baseline in AN count was significantly reduced with 1.5% ruxolitinib cream versus vehicle (least squares mean, -3.61 vs -2.42; P = .0215) with sustained improvement through week 32 with as-needed use. Patients applying ruxolitinib cream experienced fewer flares versus vehicle. Ruxolitinib cream was well tolerated, with no grade ≥3 treatment-emergent adverse events reported. LIMITATIONS: Relatively small sample size; discontinuation rates and race were imbalanced between groups. CONCLUSION: Ruxolitinib cream demonstrated greater clinical benefit versus vehicle in patients with milder HS and had a well-tolerated safety profile.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".